Investigational drug · Phase 2
STX-721
Also called: PFL-721, Escalated
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "STX-721"
First trial start
2023
Sep 26, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "STX-721", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- NSCLC
- EGFR/HER2 Exon 20 Insertion Mutation
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "STX-721" as an intervention, largest first.
Pierre Fabre MedicamentIndustry
NCT06043817 · 345 participants (planned) · Start Sep 26, 2023 · Primary completion Dec 1, 2029
Drug: STX-721/PFL-721 (Escalated); STX-721/PFL-721 (3 dose levels) and 3 more · For: Non-Small Cell Lung Cancer; NSCLC; EGFR/HER2 Exon 20 Insertion Mutation
Sites: Duarte, California; Huntington Beach, California; Irvine, California · 32 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Radiotherapy for Unresectable Soft Tissue Sarcoma.
Friedes C, Yang G, Fuller K, et al. · Surg Oncol Clin N Am 2027
- Haemophilus influenzae type B (Hib) necrotizing soft tissue infection (NSTI) in a vaccinated 16-month-old Inuit boy: a case report.
Dorey R, Morzycki A, Scott D, et al. · Int J Circumpolar Health 2026
- Effects of 5-HT2A Receptor Activation on Oxycodone Demand after Short and Long Access Self-Administration in Male and Female Rats.
Richardson CJ, McQueney AJ, Stevens T, et al. · Psychedelic Med (New Rochelle) 2026
- Toxicological effects of lanthanum strontium cobalt ferrite nanocomposite in Artemia salina and Lamellidens marginalis.
Ramanathan S, Lakshmipriya T, Gopinath SCB, et al. · 3 Biotech 2026
- 18F-FET PET for Detection of Recurrent Disease in Gliomas: Tips and Tricks for Interpretation.
Chen TL, Weber WA, Scott AM, et al. · Radiographics 2026
- A pilot study to assess the role of 12-week roflumilast treatment in non-CF bronchiectasis.
Kwok WC, To KKW, Ko FCF, et al. · Pulmonology 2026
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.